Biogen Idec, a company discovers, develops and delivers to patients worldwide innovative therapies, announced that the company has changed its name from Biogen Idec to Biogen with effect from March 23, 2015.

The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need – while honoring Biogen’s scientific heritage and legacy as a pioneer in the biotechnology industry.

Biogen Idec was created in 2003 through the merger of Biogen and IDEC Pharmaceuticals, creating one of the world’s leading research-based life sciences organizations. The company has since focused its research and commercial efforts in three core areas: neurology, immunology and hematology.

Biogen’s common stock will continue to trade on the Nasdaq Global Select Market under the symbol “BIIB,” and its CUSIP number will not change.